Bioanalysis Zone

Video: LC-MS bioanalysis of proteins via the surrogate peptide approach


Proteins and peptides represent a growing class of therapeutics due to their target specificity, lower toxicity and higher potency. Historically, these compounds have been quantified using ligand binding assays (LBAs). Recently, there has been a growing trend toward the use of LC/MS which offers the benefits of multiplexing, improved specificity, broader linear dynamic range and faster method development times. In addition, LC/MS avoids common LBA shortcomings such as cross-reactivity and anti-drug antibody effects. However, one challenge associated with quantification of proteins by LC/MS is the lack of a single standardized workflow, and the multitude of options within a workflow that make optimization difficult and time-consuming. This workshop aimed to provide practical method development guidance and comparative data for the choice of surrogate peptide, protein-level pre-fractionation, pellet digestion, peptide-level clean-up, internal standard (IS) selection, and digestion conditions. Data for infliximab, bevacizumab, and trastuzumab are presented.

Click here to view Waters company profile


Leave A Comment

Please wait...

Bioanalysis Zone New Investigator Award

Why not start this year by doing something good by nominating an early career scientist for the Bioanalysis Zone New Investigator Award. Complete the details below to register your interest!